Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bromothalonil
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Bromothalonil, also known as methyldibromo glutaronitrile (MDBGN), is a small molecule preservative widely used in personal hygiene and industrial products. It is primarily utilized as an allergen in epicutaneous patch tests to aid in the diagnosis of allergic contact dermatitis (ACD) for individuals aged six years and older. Bromothalonil is a known dermatological irritant and allergen that has been banned in many EU countries due to high rates of contact allergy. Its mechanism of action has not been clearly described[1].
- Brand names
- T.R.U.E. Test Thin-Layer Rapid Use Patch Test
- Other names
- methyldibromo glutaronitrileMDBGN
Beyond the preview
Go deeper on bromothalonil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bromothalonil.